NCT03232567Phase 2Completed

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Study sponsor: Altimmune, Inc. · ALT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2018-03-07Actual
Enrollment · participants60Actual
Source updated2024-04-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.